Acid-base addition salt containing berberine, preparation method of acid-base addition salt and application of acid-base addition salt as medicaments

A technology of base addition salt and berberine, which is applied in the field of medicine, can solve the problem of reducing the dosage of berberine, unrevealing the beneficial effect of acid-base addition salt of fenofibrate acid and berberine, small hydrochloric acid Problems such as poor dissolution rate of berberine

Active Publication Date: 2021-05-28
GUANGDONG PHARMA UNIV
View PDF14 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the dissolution rate of berberine hydrochloride is poor and the bioavailability is extremely low, which leads to the need to use high doses of berberine hydrochloride in clinical practice to achieve the expected curative effect
[0009] Chinese patent applications 201580041177.9 and 201680032575.9 respectively disclose acid-base addition salts of berberine and ursodeoxycholic acid and conjugated compounds of ursodeoxycholic acid and berberine or L-carnitine, which reduce the dosage, but does not suggest the use of acid-base addition salts of berberine and fenofibric acid, butyric acid, Gemcabene, Elafibranor, or their derivatives or structural analogues
Chinese patent application 201510986009.9 discloses a pharmaceutical composition of berberine and fe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acid-base addition salt containing berberine, preparation method of acid-base addition salt and application of acid-base addition salt as medicaments
  • Acid-base addition salt containing berberine, preparation method of acid-base addition salt and application of acid-base addition salt as medicaments
  • Acid-base addition salt containing berberine, preparation method of acid-base addition salt and application of acid-base addition salt as medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 General synthetic method of acid-base addition salt of berberine

[0027] Berberine hydrochloride (1.0 equivalent) was dissolved in hot pure water and cooled to room temperature. At the same time, dissolve the organic acid (0.6-1.2 equivalents) in absolute ethanol, and add an aqueous solution of sodium carbonate (0.6-1.2 equivalents) dropwise thereto. After the addition is completed, stir the reaction system for 30-60 minutes to obtain sodium organic acid saline solution. At a temperature of 60-80°C, add the berberine hydrochloride solution dropwise to the prepared organic acid sodium salt solution, stir for 2 hours, cool, filter and collect the solid precipitate in the reaction system, wash with a small amount of cold water, dry, and Ethanol and ethyl acetate mixed solvent carry out recrystallization to obtain the acid-base addition salt pure product of berberine, can identify the composition ratio of organic acid and berberine in the acid-base addition salt...

Embodiment 2

[0029] Example 2 Screening of lipid-lowering activity of berberine acid-base addition salt

[0030] Eight-week-old male ICR mice were adaptively fed for 5 days and randomly divided into 6 groups. The mice in the blank group and the model group were intragastrically administered with 0.5% CMC-Na solution once a day; the mice in the treatment group were intragastrically administered with the test drug once a day, both at a dose of 30 μM / kg, for 7 consecutive days. Sixteen hours before the last administration, the mice in the blank group were intraperitoneally injected with normal saline, and the mice in the other groups were injected intraperitoneally with 400 mg / kg Triton-WR1339 to establish a model. One hour after the last administration, blood was collected from the orbit, left to stand for one hour, and the serum was separated by centrifugation. The levels of TC and TG in the serum were measured. The experimental results are shown in Table 1.

[0031] Table 1: Effects of ac...

Embodiment 3

[0035] Example 3 Study on improvement of metabolic syndrome in vivo by acid-base addition salt of berberine

[0036] Eight-week-old ob / ob mice, male, were randomly divided into groups, 6 mice in each group, blank control group (blank vehicle: 0.5% sodium carboxymethylcellulose solution), and the test drug group was administered by intragastric administration once a day, respectively. Compound (30mg / kg), after continuous administration for 30 days, blood was collected from the mice on an empty stomach, and the levels of glycosylated hemoglobin, blood lipids, and liver function in the mice were measured with an automatic biochemical analyzer. The results are shown in Table 2. The mouse liver tissue was taken for sectioning, and the pathological changes of the liver tissue were observed by HE staining. The results are shown in the attached figure 1 .

[0037] Table 2: Effects of berberine acid-base addition salts on the levels of glycosylated hemoglobin, blood lipids, and liver ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel acid-alkali addition salt containing berberine and organic acid with pharmacological activity, a preparation method of the novel acid-alkali addition salt and an application of the novel acid-alkali addition salt in preparation of medicines for preventing or/and treating various diseases or dysfunction, such as diabetes, diabetic complications, dyslipidemia, and dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus combined dyslipidemia, obesity, metabolic syndrome, prediabetes mellitus, inflammation, cancer and various liver diseases or dysfunctions of statin non-tolerant patients, such as fatty liver, non-alcoholic fatty liver, non-alcoholic steatohepatitis, cholestatic liver diseases, liver transplantation versus host diseases, chronic liver diseases caused by viruses, alcoholic liver diseases and the like; the novel acid-alkali addition salt has a wide application prospect.

Description

technical field [0001] The invention relates to a novel therapeutic compound, a pharmaceutical composition, a preparation method thereof and an application in treatment, belonging to the technical field of medicine. The novel acid-base addition salt composed of berberine and pharmacologically active organic acid involved in the present invention has uniqueness and novelty in this field. Background technique [0002] Metabolic syndrome is a common disease characterized by abnormal glucose and lipid metabolism, accompanied by elevated low-density lipoprotein and low high-density lipoprotein cholesterol. The common symptoms are obesity, diabetes, hyperlipidemia, atherosclerosis Cirrhosis and fatty liver, etc. Among them, diabetic patients often have hyperlipidemia, cardiovascular disease, diabetic nephropathy, diabetic neuropathy and other diseases. [0003] According to the World Health Organization, more than 220 million people worldwide suffer from diabetes. Among them, Chi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D455/03C07C59/90C07C59/305C07C53/124C07C323/22A61P1/16A61P31/12A61P3/10A61P3/06A61P3/04A61P3/00A61P9/10A61P29/00A61P35/00A61K31/4375A61K31/216A61K31/205
CPCC07D455/03C07C59/90C07C59/305C07C53/124C07C323/22A61P1/16A61P31/12A61P3/10A61P3/06A61P3/04A61P3/00A61P9/10A61P29/00A61P35/00
Inventor 李政张陆勇蔡宗余
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap